JOURNAL TRANSCRIPT
As Passed by the House 132nd General Assembly Regular Session
H. B. No. 535
2017-2018 Representative Gavarone Cosponsors: Representatives Young, Brown, Patton, Stein, Arndt, Hambley, Kick, Smith, R., Ryan, Sprague, Ginter, Boyd, Anielski, Antani, Antonio, Blessing, Boggs, Butler, Carfagna, Clyde, Craig, Cupp, Dever, Duffey, Edwards, Faber, Galonski, Green, Greenspan, Hill, Holmes, Hoops, Landis, Lanese, LaTourette, Leland, Lepore-Hagan, Manning, Miller, O'Brien, Patterson, Pelanda, Perales, Reineke, Rogers, Scherer, Schuring, Sheehy, Strahorn, Sykes, West, Wiggam
A BILL To amend sections 4729.01, 4729.44, 4729.75,
1
4729.79, and 4729.85 and to enact sections
2
3727.25 and 4765.45 of the Revised Code to
3
require certain reports regarding overdoses and
4
naloxone, to include naltrexone within the Ohio
5
Automated Rx Reporting System, and to name this
6
act the "Opioid Data and Communication Expansion
7
Act."
8
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:
Section 1. That sections 4729.01, 4729.44, 4729.75,
9
4729.79, and 4729.85 be amended and sections 3727.25 and 4765.45
10
of the Revised Code be enacted to read as follows:
11
Sec. 3727.25. (A) Each hospital shall report to the
12
department of health on a monthly basis and in a manner
13
prescribed by the department all of the following information
14
for the previous month:
15
H. B. No. 535 As Passed by the House
(1) The total number of drug overdose cases brought to the hospital for treatment; (2) Of the number described in division (A)(1) of this
Page 2
16 17 18
section, the number that resulted in death and the number that
19
did not result in death.
20
When submitting reports, the hospital shall not include
21
any information that identifies or tends to identify specific
22
patients.
23
(B) Each month, the department shall compile the
24
information it receives under division (A) of this section and
25
shall publish the information on its internet web site.
26
(C) The department may adopt rules as necessary to
27
implement this section. The rules shall be adopted in accordance
28
with Chapter 119. of the Revised Code.
29
Sec. 4729.01. As used in this chapter:
30
(A) "Pharmacy," except when used in a context that refers
31
to the practice of pharmacy, means any area, room, rooms, place
32
of business, department, or portion of any of the foregoing
33
where the practice of pharmacy is conducted.
34
(B) "Practice of pharmacy" means providing pharmacist care
35
requiring specialized knowledge, judgment, and skill derived
36
from the principles of biological, chemical, behavioral, social,
37
pharmaceutical, and clinical sciences. As used in this division,
38
"pharmacist care" includes the following:
39
(1) Interpreting prescriptions;
40
(2) Dispensing drugs and drug therapy related devices;
41
(3) Compounding drugs;
42
H. B. No. 535 As Passed by the House
(4) Counseling individuals with regard to their drug
Page 3
43
therapy, recommending drug therapy related devices, and
44
assisting in the selection of drugs and appliances for treatment
45
of common diseases and injuries and providing instruction in the
46
proper use of the drugs and appliances;
47
(5) Performing drug regimen reviews with individuals by
48
discussing all of the drugs that the individual is taking and
49
explaining the interactions of the drugs;
50
(6) Performing drug utilization reviews with licensed
51
health professionals authorized to prescribe drugs when the
52
pharmacist determines that an individual with a prescription has
53
a drug regimen that warrants additional discussion with the
54
prescriber;
55
(7) Advising an individual and the health care
56
professionals treating an individual with regard to the
57
individual's drug therapy;
58
(8) Acting pursuant to a consult agreement with one or
59
more physicians authorized under Chapter 4731. of the Revised
60
Code to practice medicine and surgery or osteopathic medicine
61
and surgery, if an agreement has been established;
62
(9) Engaging in the administration of immunizations to the extent authorized by section 4729.41 of the Revised Code; (10) Engaging in the administration of drugs to the extent authorized by section 4729.45 of the Revised Code. (C) "Compounding" means the preparation, mixing,
63 64 65 66 67
assembling, packaging, and labeling of one or more drugs in any
68
of the following circumstances:
69
(1) Pursuant to a prescription issued by a licensed health
70
H. B. No. 535 As Passed by the House
professional authorized to prescribe drugs; (2) Pursuant to the modification of a prescription made in accordance with a consult agreement; (3) As an incident to research, teaching activities, or chemical analysis;
Page 4
71 72 73 74 75
(4) In anticipation of orders for drugs pursuant to
76
prescriptions, based on routine, regularly observed dispensing
77
patterns;
78
(5) Pursuant to a request made by a licensed health
79
professional authorized to prescribe drugs for a drug that is to
80
be used by the professional for the purpose of direct
81
administration to patients in the course of the professional's
82
practice, if all of the following apply:
83
(a) At the time the request is made, the drug is not
84
commercially available regardless of the reason that the drug is
85
not available, including the absence of a manufacturer for the
86
drug or the lack of a readily available supply of the drug from
87
a manufacturer.
88
(b) A limited quantity of the drug is compounded and provided to the professional. (c) The drug is compounded and provided to the
89 90 91
professional as an occasional exception to the normal practice
92
of dispensing drugs pursuant to patient-specific prescriptions.
93
(D) "Consult agreement" means an agreement that has been entered into under section 4729.39 of the Revised Code.
94 95
(E) "Drug" means:
96
(1) Any article recognized in the United States
97
H. B. No. 535 As Passed by the House
Page 5
pharmacopoeia and national formulary, or any supplement to them,
98
intended for use in the diagnosis, cure, mitigation, treatment,
99
or prevention of disease in humans or animals;
100
(2) Any other article intended for use in the diagnosis,
101
cure, mitigation, treatment, or prevention of disease in humans
102
or animals;
103
(3) Any article, other than food, intended to affect the
104
structure or any function of the body of humans or animals;
105
(4) Any article intended for use as a component of any
106
article specified in division (E)(1), (2), or (3) of this
107
section; but does not include devices or their components,
108
parts, or accessories.
109
(F) "Dangerous drug" means any of the following:
110
(1) Any drug to which either of the following applies:
111
(a) Under the "Federal Food, Drug, and Cosmetic Act," 52
112
Stat. 1040 (1938), 21 U.S.C.A. 301, as amended, the drug is
113
required to bear a label containing the legend "Caution: Federal
114
law prohibits dispensing without prescription" or "Caution:
115
Federal law restricts this drug to use by or on the order of a
116
licensed veterinarian" or any similar restrictive statement, or
117
the drug may be dispensed only upon a prescription;
118
(b) Under Chapter 3715. or 3719. of the Revised Code, the drug may be dispensed only upon a prescription. (2) Any drug that contains a schedule V controlled
119 120 121
substance and that is exempt from Chapter 3719. of the Revised
122
Code or to which that chapter does not apply;
123
(3) Any drug intended for administration by injection into the human body other than through a natural orifice of the human
124 125
H. B. No. 535 As Passed by the House
body;
Page 6
126 (4) Any drug that is a biological product, as defined in
section 3715.01 of the Revised Code. (G) "Federal drug abuse control laws" has the same meaning as in section 3719.01 of the Revised Code.
127 128 129 130
(H) "Prescription" means all of the following:
131
(1) A written, electronic, or oral order for drugs or
132
combinations or mixtures of drugs to be used by a particular
133
individual or for treating a particular animal, issued by a
134
licensed health professional authorized to prescribe drugs;
135
(2) For purposes of sections 2925.61, 4723.488, 4729.44,
136
4730.431, and 4731.94 of the Revised Code, a written,
137
electronic, or oral order for naloxone issued to and in the name
138
of a family member, friend, or other individual in a position to
139
assist an individual who there is reason to believe is at risk
140
of experiencing an opioid-related overdose.
141
(3) For purposes of section 4729.44 of the Revised Code, a
142
written, electronic, or oral order for naloxone issued to and in
143
the name of either of the following:
144
(a) An individual who there is reason to believe is at risk of experiencing an opioid-related overdose;
145 146
(b) A family member, friend, or other individual in a
147
position to assist an individual who there is reason to believe
148
is at risk of experiencing an opioid-related overdose.
149
(4) For purposes of sections 4723.4810, 4729.282,
150
4730.432, and 4731.93 of the Revised Code, a written,
151
electronic, or oral order for a drug to treat chlamydia,
152
gonorrhea, or trichomoniasis issued to and in the name of a
153
H. B. No. 535 As Passed by the House
Page 7
patient who is not the intended user of the drug but is the
154
sexual partner of the intended user;
155
(4) (5) For purposes of sections 3313.7110, 3313.7111,
156
3314.143, 3326.28, 3328.29, 4723.483, 4729.88, 4730.433,
157
4731.96, and 5101.76 of the Revised Code, a written, electronic,
158
or oral order for an epinephrine autoinjector issued to and in
159
the name of a school, school district, or camp;
160
(5) (6) For purposes of Chapter 3728. and sections
161
4723.483, 4729.88, 4730.433, and 4731.96 of the Revised Code, a
162
written, electronic, or oral order for an epinephrine
163
autoinjector issued to and in the name of a qualified entity, as
164
defined in section 3728.01 of the Revised Code.
165
(I) "Licensed health professional authorized to prescribe
166
drugs" or "prescriber" means an individual who is authorized by
167
law to prescribe drugs or dangerous drugs or drug therapy
168
related devices in the course of the individual's professional
169
practice, including only the following:
170
(1) A dentist licensed under Chapter 4715. of the Revised Code;
171 172
(2) A clinical nurse specialist, certified nurse-midwife,
173
or certified nurse practitioner who holds a current, valid
174
license to practice nursing as an advanced practice registered
175
nurse issued under Chapter 4723. of the Revised Code;
176
(3) An optometrist licensed under Chapter 4725. of the
177
Revised Code to practice optometry under a therapeutic
178
pharmaceutical agents certificate;
179
(4) A physician authorized under Chapter 4731. of the
180
Revised Code to practice medicine and surgery, osteopathic
181
medicine and surgery, or podiatric medicine and surgery;
182
H. B. No. 535 As Passed by the House
(5) A physician assistant who holds a license to practice
Page 8
183
as a physician assistant issued under Chapter 4730. of the
184
Revised Code, holds a valid prescriber number issued by the
185
state medical board, and has been granted physician-delegated
186
prescriptive authority;
187
(6) A veterinarian licensed under Chapter 4741. of the Revised Code. (J) "Sale" or "sell" includes any transaction made by any
188 189 190
person, whether as principal proprietor, agent, or employee, to
191
do or offer to do any of the following: deliver, distribute,
192
broker, exchange, gift or otherwise give away, or transfer,
193
whether the transfer is by passage of title, physical movement,
194
or both.
195
(K) "Wholesale sale" and "sale at wholesale" mean any sale
196
in which the purpose of the purchaser is to resell the article
197
purchased or received by the purchaser.
198
(L) "Retail sale" and "sale at retail" mean any sale other than a wholesale sale or sale at wholesale.
199 200
(M) "Retail seller" means any person that sells any
201
dangerous drug to consumers without assuming control over and
202
responsibility for its administration. Mere advice or
203
instructions regarding administration do not constitute control
204
or establish responsibility.
205
(N) "Price information" means the price charged for a
206
prescription for a particular drug product and, in an easily
207
understandable manner, all of the following:
208
(1) The proprietary name of the drug product;
209
(2) The established (generic) name of the drug product;
210
H. B. No. 535 As Passed by the House
(3) The strength of the drug product if the product
Page 9
211
contains a single active ingredient or if the drug product
212
contains more than one active ingredient and a relevant strength
213
can be associated with the product without indicating each
214
active ingredient. The established name and quantity of each
215
active ingredient are required if such a relevant strength
216
cannot be so associated with a drug product containing more than
217
one ingredient.
218
(4) The dosage form;
219
(5) The price charged for a specific quantity of the drug
220
product. The stated price shall include all charges to the
221
consumer, including, but not limited to, the cost of the drug
222
product, professional fees, handling fees, if any, and a
223
statement identifying professional services routinely furnished
224
by the pharmacy. Any mailing fees and delivery fees may be
225
stated separately without repetition. The information shall not
226
be false or misleading.
227
(O) "Wholesale distributor of dangerous drugs" or
228
"wholesale distributor" means a person engaged in the sale of
229
dangerous drugs at wholesale and includes any agent or employee
230
of such a person authorized by the person to engage in the sale
231
of dangerous drugs at wholesale.
232
(P) "Manufacturer of dangerous drugs" or "manufacturer"
233
means a person, other than a pharmacist or prescriber, who
234
manufactures dangerous drugs and who is engaged in the sale of
235
those dangerous drugs.
236
(Q) "Terminal distributor of dangerous drugs" or "terminal
237
distributor" means a person who is engaged in the sale of
238
dangerous drugs at retail, or any person, other than a
239
H. B. No. 535 As Passed by the House
Page 10
manufacturer, repackager, outsourcing facility, third-party
240
logistics provider, wholesale distributor, or pharmacist, who
241
has possession, custody, or control of dangerous drugs for any
242
purpose other than for that person's own use and consumption.
243
"Terminal distributor" includes pharmacies, hospitals, nursing
244
homes, and laboratories and all other persons who procure
245
dangerous drugs for sale or other distribution by or under the
246
supervision of a pharmacist or licensed health professional
247
authorized to prescribe drugs.
248
(R) "Promote to the public" means disseminating a
249
representation to the public in any manner or by any means,
250
other than by labeling, for the purpose of inducing, or that is
251
likely to induce, directly or indirectly, the purchase of a
252
dangerous drug at retail.
253
(S) "Person" includes any individual, partnership,
254
association, limited liability company, or corporation, the
255
state, any political subdivision of the state, and any district,
256
department, or agency of the state or its political
257
subdivisions.
258
(T) "Animal shelter" means a facility operated by a humane
259
society or any society organized under Chapter 1717. of the
260
Revised Code or a dog pound operated pursuant to Chapter 955. of
261
the Revised Code.
262
(U) "Food" has the same meaning as in section 3715.01 of the Revised Code. (V) "Pain management clinic" has the same meaning as in section 4731.054 of the Revised Code.
263 264 265 266
(W) "Investigational drug or product" means a drug or
267
product that has successfully completed phase one of the United
268
H. B. No. 535 As Passed by the House
Page 11
States food and drug administration clinical trials and remains
269
under clinical trial, but has not been approved for general use
270
by the United States food and drug administration.
271
"Investigational drug or product" does not include controlled
272
substances in schedule I, as established pursuant to section
273
3719.41 of the Revised Code, and as amended.
274
(X) "Product," when used in reference to an
275
investigational drug or product, means a biological product,
276
other than a drug, that is made from a natural human, animal, or
277
microorganism source and is intended to treat a disease or
278
medical condition.
279
(Y) "Third-party logistics provider" means a person that
280
provides or coordinates warehousing or other logistics services
281
pertaining to dangerous drugs including distribution, on behalf
282
of a manufacturer, wholesale distributor, or terminal
283
distributor of dangerous drugs, but does not take ownership of
284
the drugs or have responsibility to direct the sale or
285
disposition of the drugs.
286
(Z) "Repackager of dangerous drugs" or "repackager" means
287
a person that repacks and relabels dangerous drugs for sale or
288
distribution.
289
(AA) "Outsourcing facility" means a facility that is
290
engaged in the compounding and sale of sterile drugs and is
291
registered as an outsourcing facility with the United States
292
food and drug administration.
293
Sec. 4729.44. (A) As used in this section:
294
(1) "Board of health" means a board of health of a city or
295
general health district or an authority having the duties of a
296
board of health under section 3709.05 of the Revised Code.
297
H. B. No. 535 As Passed by the House
(2) "Physician" means an individual authorized under
Page 12
298
Chapter 4731. of the Revised Code to practice medicine and
299
surgery, osteopathic medicine and surgery, or podiatric medicine
300
and surgery.
301
(B) If use of the protocol developed pursuant to rules
302
adopted under division (G) of this section has been authorized
303
under section 3707.56 or 4731.942 of the Revised Code, a
304
pharmacist or pharmacy intern may dispense naloxone without a
305
prescription to either of the following in accordance with that
306
protocol:
307
(1) An individual who there is reason to believe is
308
experiencing or at risk of experiencing an opioid-related
309
overdose;
310
(2) A family member, friend, or other person individual in
311
a position to assist an individual who there is reason to
312
believe is at risk of experiencing an opioid-related overdose.
313
(C) A pharmacist or pharmacy intern who dispenses naloxone
314
under this section shall instruct the individual to whom
315
naloxone is dispensed to summon emergency services as soon as
316
practicable either before or after administering naloxone.
317
(D) A pharmacist may document on a prescription form the
318
dispensing of naloxone by the pharmacist or a pharmacy intern
319
supervised by the pharmacist on a prescription form. The form
320
may be assigned a number for record-keeping purposes.
321
(E) This section does not affect the authority of a
322
pharmacist or pharmacy intern to fill or refill a prescription
323
for naloxone.
324
(F) A board of health that in good faith authorizes a pharmacist or pharmacy intern to dispense naloxone without a
325 326
H. B. No. 535 As Passed by the House
Page 13
prescription in accordance with a protocol developed pursuant to
327
rules adopted under division (G) of this section is not liable
328
for or subject to any of the following for any action or
329
omission of the individual to whom the naloxone is dispensed:
330
damages in any civil action, prosecution in any criminal
331
proceeding, or professional disciplinary action.
332
A physician who in good faith authorizes a pharmacist or
333
pharmacy intern to dispense naloxone without a prescription in
334
accordance with a protocol developed pursuant to rules adopted
335
under division (G) of this section is not liable for or subject
336
to any of the following for any action or omission of the
337
individual to whom the naloxone is dispensed: damages in any
338
civil action, prosecution in any criminal proceeding, or
339
professional disciplinary action.
340
A pharmacist or pharmacy intern authorized under this
341
section to dispense naloxone without a prescription who does so
342
in good faith is not liable for or subject to any of the
343
following for any action or omission of the individual to whom
344
the naloxone is dispensed: damages in any civil action,
345
prosecution in any criminal proceeding, or professional
346
disciplinary action.
347
(G) The state board of pharmacy shall, after consulting
348
with the department of health and state medical board, adopt
349
rules to implement this section. The rules shall specify a
350
protocol under which pharmacists or pharmacy interns may
351
dispense naloxone without a prescription.
352
All rules adopted under this section shall be adopted in accordance with Chapter 119. of the Revised Code. Sec. 4729.75. The state board of pharmacy may establish
353 354 355
H. B. No. 535 As Passed by the House
Page 14
and maintain a drug database. The board shall use the drug
356
database to monitor the misuse and diversion of the following:
357
controlled substances, as defined in section 3719.01 of the
358
Revised Code; medical marijuana, as authorized under Chapter
359
3796. of the Revised Code; and other dangerous drugs the board
360
includes in the database pursuant to rules adopted under section
361
4729.84 of the Revised Code. In
362
The board also shall use the drug database to monitor naltrexone. In establishing and maintaining the database, the board
363 364 365
shall electronically collect information pursuant to sections
366
4729.77, 4729.771, 4729.772, 4729.78, and 4729.79 of the Revised
367
Code and shall disseminate information as authorized or required
368
by sections 4729.80 and 4729.81 of the Revised Code. The board's
369
collection and dissemination of information shall be conducted
370
in accordance with rules adopted under section 4729.84 of the
371
Revised Code.
372
Sec. 4729.79. (A) If the state board of pharmacy
373
establishes and maintains a drug database pursuant to section
374
4729.75 of the Revised Code, each licensed health professional
375
authorized to prescribe drugs, except as provided in division
376
(C) of this section, who personally furnishes to a patient a
377
controlled substance, naltrexone, or other dangerous drug the
378
board includes in the database pursuant to rules adopted under
379
section 4729.84 of the Revised Code shall submit to the board
380
the following information:
381
(1) Prescriber identification;
382
(2) Patient identification;
383
(3) Date drug was furnished by the prescriber;
384
H. B. No. 535 As Passed by the House
(4) Indication of whether the drug furnished is new or a refill; (5) Name, strength, and national drug code of drug furnished;
Page 15
385 386 387 388
(6) Quantity of drug furnished;
389
(7) Number of days' supply of drug furnished;
390
(8) Source of payment for the drug furnished;
391
(9) Identification of the owner of the drug furnished.
392
(B)(1) The information shall be transmitted as specified
393
by the board in rules adopted under section 4729.84 of the
394
Revised Code.
395
(2) The information shall be submitted electronically in
396
the format specified by the board, except that the board may
397
grant a waiver allowing the prescriber to submit the information
398
in another format.
399
(3) The information shall be submitted in accordance with
400
any time limits specified by the board, except that the board
401
may grant an extension if either of the following occurs:
402
(a) The prescriber's transmission system suffers a
403
mechanical or electronic failure, or the prescriber cannot meet
404
the deadline for other reasons beyond the prescriber's control.
405
(b) The board is unable to receive electronic submissions.
406
(C)(1) The information required to be submitted under
407
division (A) of this section may be submitted on behalf of the
408
prescriber by the owner of the drug being personally furnished
409
or by a delegate approved by that owner.
410
(2) The requirements of this section to submit information
411
H. B. No. 535 As Passed by the House
to the board do not apply to a prescriber who is a veterinarian. (D) If the board becomes aware of a prescriber's failure
Page 16
412 413
to comply with this section, the board shall notify the
414
government entity responsible for licensing the prescriber.
415
Sec. 4729.85. If the state board of pharmacy establishes
416
and maintains a drug database pursuant to section 4729.75 of the
417
Revised Code, the board shall prepare reports regarding the
418
database and present or submit them in accordance with both of
419
the following:
420
(A) The board shall present a biennial report to the
421
standing committees of the house of representatives and the
422
senate that are primarily responsible for considering health and
423
human services issues. Each report shall include all of the
424
following:
425
(1) The cost to the state of establishing and maintaining the database; (2) Information from the board, terminal distributors of
426 427 428
dangerous drugs, prescribers, and retail dispensaries licensed
429
under Chapter 3796. of the Revised Code regarding the board's
430
effectiveness in providing information from the database;
431
(3) The board's timeliness in transmitting information from the database.
432 433
(B) The board shall submit a semiannual report to the
434
governor, the president of the senate, the speaker of the house
435
of representatives, the attorney general, the chairpersons of
436
the standing committees of the house of representatives and the
437
senate that are primarily responsible for considering health and
438
human services issues, the department of public safety, the
439
state dental board, the board of nursing, the state vision
440
H. B. No. 535 As Passed by the House
Page 17
professionals board, the state medical board, and the state
441
veterinary medical licensing board. The state board of pharmacy
442
shall make the report available to the public on its internet
443
web site. Each report submitted shall include all of the
444
following for the period covered by the report:
445
(1) An aggregate of the information submitted to the board
446
under section 4729.77 of the Revised Code regarding
447
prescriptions for controlled substances containing opioids,
448
including all of the following:
449
(a) The number of prescribers who issued the prescriptions; (b) The number of patients to whom the controlled substances were dispensed; (c) The average quantity of the controlled substances dispensed per prescription; (d) The average daily morphine equivalent dose of the controlled substances dispensed per prescription. (2) An aggregate of the information submitted to the board
450 451 452 453 454 455 456 457 458
under section 4729.79 of the Revised Code regarding controlled
459
substances containing opioids that have been personally
460
furnished to a patient by a prescriber, other than a prescriber
461
who is a veterinarian, including all of the following:
462
(a) The number of prescribers who personally furnished the controlled substances; (b) The number of patients to whom the controlled substances were personally furnished; (c) The average quantity of the controlled substances that were furnished at one time;
463 464 465 466 467 468
H. B. No. 535 As Passed by the House
(d) The average daily morphine equivalent dose of the controlled substances that were furnished at one time. (3) An aggregate of the information submitted to the board
Page 18
469 470 471
under section 4729.771 of the Revised Code regarding medical
472
marijuana;
473
(4) An aggregate of the information submitted to the board
474
under sections 4729.77 and 4729.79 of the Revised Code regarding
475
naltrexone, including all of the following:
476
(a) The number of prescribers who issued the prescriptions for or personally furnished the drug; (b) The number of patients to whom the drug was dispensed or personally furnished; (c) The average quantity of the drug dispensed per prescription or furnished at one time. Sec. 4765.45. (A) If the department of public safety
477 478 479 480 481 482 483
collects any of the following information regarding the
484
administration of naloxone by emergency medical service
485
personnel or any firefighter or volunteer firefighter, the
486
department of public safety shall report the information to the
487
department of health on a monthly basis and in a manner
488
prescribed by the department of health:
489
(1) The five-digit postal zip code plus four-digit add-on where the naloxone was administered;
490 491
(2) The date on which the naloxone was administered;
492
(3) The number of doses administered;
493
(4) The name of the emergency medical service organization
494
or fire department that administered the naloxone;
495
H. B. No. 535 As Passed by the House
Page 19
(5) Whether or not an overdose was reversed;
496
(6) Whether the individual was taken to a hospital.
497
When reporting to the department of health, the department
498
of public safety shall not include any information that
499
identifies or tends to identify specific individuals to whom
500
naloxone was administered.
501
(B) Each month, the department of health shall compile the
502
information received under division (A) of this section,
503
organize it by county, and forward it to each board of alcohol,
504
drug addiction, and mental health services in this state.
505
(C) The department of health may adopt rules as necessary
506
to implement this section. The rules shall be adopted in
507
accordance with Chapter 119. of the Revised Code.
508
Section 2. That existing sections 4729.01, 4729.44,
509
4729.75, 4729.79, and 4729.85 of the Revised Code are hereby
510
repealed.
511
Section 3. This act shall be known as the "Opioid Data and Communication Expansion Act."
512 513